Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children with Neurofibromatosis Type 1 Related Plexiform Neurofibromas

Trial Identifier: D1346C00015
Sponsor: AstraZeneca
Collaborator:
Merck Sharp & Dohme Corp.
NCTID:: NCT05101148
Start Date: July 2021
Primary Completion Date: April 2022
Study Completion Date: March 2023

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version

Trial Locations

Country Location
ES Barcelona, ES, 08950
ES Madrid, ES, 28009
PL Bydgoszcz, PL, 85-094
PL Gdańsk, PL, 80-952
PL Warszawa, PL, 02-091
RU Moscow, RU, 115478
RU Moscow, RU, 119620
RU Moscow, RU, 125412
US, MN Rochester, MN, US, 55905
US, OH Akron, OH, US, 44308
US, PA Philadelphia, PA, US, 19104
US, UT Salt Lake City, UT, US, 84108